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Background
Along with risk factors like smoking, hypertension,
atherosclerosis and low choroidal blood flow, genetic
susceptibility is a primary contributor to the develop-
ment and progression of wet age-related macular degen-
eration (AMD). Vascular endothelial growth factor
(VEGF) is a central angiogenic regulator and there is
general agreement now that it is one of the most impor-
tant triggers for the progression of neovascular AMD. In
the present study we tested the hypothesis that VEGF
gene polymorphisms play a role in the treatment success
with VEGF inhibitors in patients with CNV.
Methods
One-hundred-sixty-two eyes of 143 patients with neo-
vascular AMD who were scheduled for their first treat-
ment with intravitreally administered ranibizumab were
included in this trial. All patients were aged over
50 years and had angiographically verified neovascular
AMD. Blood from the finger pad was collected on blood
cards for genotyping for the VEGF polymorphisms
rs1413711, rs3025039, rs2010963, rs833061, rs699947,
rs3024997 and rs1005230. At each follow up visit, visual
acuity was reassessed and an ophthalmic examination
was carried out. The number of retreatments as well as
the visual acuity outcome was analyzed in dependence
of the VEGF polymorphisms.
Results
The included patients were reinjected with ranibizumab
2 to 19 times, resulting in a total treatment period of
42 to 1182 days. Neither the number of retreatments
nor the visual acuity outcome was associated with any
of the studied haplotypes.
Conclusions
The success of anti VEGF treatment is not dependent
on VEGF gene polymorphisms.
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